artículo
Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report
Fecha
2017Registro en:
0717-6163
0034-9887
MEDLINE:29424412
WOS:000416126800018
Autor
Gustavo Rivera, O. A.
Oscar Corsi, S. B.
Andres Pavlovic, J. B.
Andres Aizman, S.
Pablo Varas, A.
Institución
Resumen
Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.